ITI Life Sciences Launches New Stem Cell Technology Program
A new ?9.5 million R&D program has been launched by ITI Life Sciences (Dundee, Scotland, www.itilifesciences.com) to develop an automated process to produce high-quality human stem cells.
A new £9.5 million R&D program has been launched by ITI Life Sciences (Dundee, Scotland, www.itilifesciences.com) to develop an automated process to produce high-quality human stem cells. This capability will put Scotland at the forefront of stem cell research as well as bring closer the use of stem cells as therapeutics.
As part of this three-year program, the Swedish biotech company Cellartis AB, a stem cell company and a provider of ethically derived human embryonic stem cell (hES) lines, is setting up an R&D and manufacturing facility in Dundee.
The ITI program will also involve the University of Glasgow, which brings expertise in the molecular mechanisms that control cell signaling and development. The work will be carried out by the University’s Faculty of Medicine and Faculty of Biomedical and Life Sciences. In creating this program, ITI Life Science hopes to solve some of the main problems associated with producing high volumes of quality stem cells.
The ITI program will use pre-existing hES cell lines. This phase of the program will be deemed a success if it results in a robust and standardized procedure for generating multiple human cell lines of interest to the pharmaceutical industry from undifferentiated hES cells. ITI Life Sciences will own all intellectual property generated by the program.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
FDA Reopens Comment Period on HCP Immunogenicity Risk of Follow-on Recombinant Peptides
January 2nd 2025FDA is reopening the comment period for the Federal Register Notice, “Evaluating the Immunogenicity Risk of Host Cell Proteins in Follow-on Recombinant Peptide Products: Establishment of a Public Docket: Request for Information and Comments”, until March 3, 2025.
